Mirati Therapeutics Inc
Gesloten
SectorGezondheidszorg
0
Overzicht
Wijziging aandelenprijs
24u
Min
Max
Aanbevelingen | Neutraal |
|---|---|
12 Maanden Prognose | -0.05% downside |
Nieuwssentiment
By Acuity
58%
42%
266 / 344 Rangschikking in Healthcare
Mirati Therapeutics Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Mirati Therapeutics Inc Prognose
Koersdoel
By TipRanks
-0.05% neerwaarts potentieel
12 Maanden Prognose
Gemiddelde 58.67 USD -0.05%
Hoogste 59 USD
Laagste 58 USD
Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Mirati Therapeutics Inc - Dist. in de afgelopen 3 maanden.
Sentiment
By Acuity
266 / 344 Rangschikking in Gezondheidszorg
Nieuwssentiment
Bullish Bewijs
Volatiliteit
Onder gemiddelde
Nieuws Volume (RCV)
Boven gemiddelde
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
EBITDA
Operationele winst
$
Over Mirati Therapeutics Inc
Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.
